GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Total Payout Yield %

CTOR (Citius Oncology) Total Payout Yield % : 0.00 (As of Jan. 19, 2025)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Total Payout Yield %?

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Citius Oncology's current Total Payout Yield % is 0.00%.


Citius Oncology Total Payout Yield % Historical Data

The historical data trend for Citius Oncology's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Total Payout Yield % Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Total Payout Yield %
- - -

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Total Payout Yield % - - -

Competitive Comparison of Citius Oncology's Total Payout Yield %

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Citius Oncology's Total Payout Yield % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Total Payout Yield % falls into.



Citius Oncology Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Citius Oncology's Total Payout Yield % for the fiscal year that ended in Sep. 2024 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (0 + 0 + 0) / 99.457836
=0.00%

Citius Oncology's annualized Total Payout Yield % for the quarter that ended in Sep. 2024 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (0 + 0 + 0) * 1 / 99.457836
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Citius Oncology Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


Citius Oncology Total Payout Yield % Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Total Payout Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Citius Oncology Business Description

Traded in Other Exchanges
N/A
Address
420 Lexington Ave, Suite 2446, New York, NY, USA, 10170
Website
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.

Citius Oncology Headlines